
The U.S. Food and Drug Administration has granted approval for Astellas Pharma's Padcev in conjunction with Merck's Keytruda to treat a specific type of bladder cancer. This follows the FDA's earlier accelerated approval in April for patients ineligible for cisplatin chemotherapy. The decision stems from a successful late-stage trial, meeting key efficacy criteria in overall survival and progression-free survival. Astellas, previously endorsed for its chronic eye disease drug Izervay, collaborated with Seagen (Pfizer-owned) in developing Padcev. This regulatory nod bolsters Astellas' portfolio in the pharmaceutical landscape.
Like
Save
Share